Biogen Entered into a License and Collaboration Agreement with Alectos to Develop and Commercialize AL01811 for Parkinson’s Disease
Shots:
- Alectos to receive $15M for an exclusive global license to AL01811 & additional unnamed backup molecules & is eligible to receive ~$77.5M in development milestones & $630M in commercial milestones along with royalties
- Additionally, both companies will work on preclinical activities for AL01811 (selective GBA2 inhibitor). Biogen will be responsible for all development, regulatory, manufacturing, and commercial activities and costs of the product after AL01811 is advanced to the clinic
- The collaboration will combine Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders to develop AL01811 for patients with PD
Ref: Globenewswire| Image: Biogen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
